^
    Back
    Association details:
    Biomarker:EGFR mutation + Chr 14q31.1-q31.3
    Cancer:Non Small Cell Lung Cancer
    Drug Class:EGFR inhibitor
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    Pharmgenomics Pers Med
    Title:

    Chromosomal Copy Number Variation Predicts EGFR-TKI Response and Prognosis for Patients with Non-Small Cell Lung Cancer

    Published date:
    09/19/2023
    Excerpt:
    Conversely, EGFR-mutated patients with a gain in 14q31.1-q31.3 demonstrated favorable TKI responses and relatively extended PFS (P = 0.005).
    DOI:
    10.2147/PGPM.S418320